REVIVE LAB UAE maintains a fixed, deliberately chosen catalog of research peptides — including Tesamorelin, Retatrutide, BPC-157, TB-500, GHK-Cu, MOTS-c, NAD+, and Semax. Each catalog compound is sourced, tested, and documented with lot-specific Certificates of Analysis, giving researchers verifiable quality information for what they are actually purchasing.
IGF-1 LR3 has not been added to this set. This is a deliberate catalog decision, not a reflection of IGF-1 LR3's regulatory category relative to other unscheduled research peptides.
Tesamorelin is a useful example of what catalog inclusion looks like: it is a growth-hormone-releasing hormone (GHRH) analog with an established clinical research history and regulatory approval history in specific therapeutic contexts, documented and tested as part of REVIVE LAB UAE's catalog.
This documentation history is part of what distinguishes a catalog compound from a non-catalog one — it is not simply about whether a compound is legal to research, but about whether REVIVE LAB UAE has chosen to source, verify, and stand behind it with lot-specific testing.
IGF-1 LR3, by contrast, has never progressed through any pharmaceutical development or approval process and exists purely as an unregulated research chemical. It carries no REVIVE LAB UAE-issued Certificate of Analysis, no listed price, no stock status, and no checkout path — because it simply is not part of the catalog REVIVE LAB UAE has built.
This is the clearest practical distinction for researchers: catalog compounds come with REVIVE LAB UAE's documented sourcing and testing; IGF-1 LR3 does not, because REVIVE LAB UAE does not supply it at all.
Tesamorelin and IGF-1 LR3 do sit in the same general growth-hormone signaling axis — Tesamorelin upstream, stimulating endogenous GH release, and IGF-1 LR3 downstream, acting directly at the IGF-1 receptor. Researchers interested in this axis broadly may find that mechanistic relationship informative even though only one of the two compounds is actually available through REVIVE LAB UAE.
Mechanistic proximity within a signaling pathway does not translate into catalog availability — the two are separate questions entirely.
This comparison is a useful general template: when evaluating any research-peptide supplier, ask what is actually documented with lot-specific testing versus what is merely discussed informationally. REVIVE LAB UAE aims to be transparent about that distinction across its own site, including for compounds like IGF-1 LR3 that it explicitly does not sell.
Readers can view REVIVE LAB UAE's current, documented catalog directly for the authoritative list of what is actually available.